Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Toward the complete understanding of the pathogenic mechanism of clioquinol-induced subacute myelo-optic neuropathy (SMON)].
Nihon Yakurigaku Zasshi
March 2024
Radioisotope Center, Kyoto Prefectural University of Medicine.
Clioquinol was extensively used as an amebicide to treat indigestion and diarrhea in the mid-1900s. However, it was withdrawn from the market in Japan because its use was epidemiologically linked to an increase in the incidence of subacute myelo-optic neuropathy (SMON). SMON is characterized by the subacute onset of sensory and motor disturbances in the lower extremities with occasional visual impairments, which are preceded by abdominal symptoms.
View Article and Find Full Text PDFNQO1 protects against clioquinol toxicity.
Front Pharmacol
October 2022
School of Pharmacy, University of Tasmania, Hobart, TAS, Australia.
Clioquinol (CQ) was widely used as oral antibiotic before being taken off the market in many countries in 1970, after it was linked to subacute myelo-optic neuropathy (SMON) in Japan, leading to vision loss with many patients left wheelchair-bound. The common pathology of CQ-associated SMON was reproduced in animals but none of the proposed modes of toxicity explained the restriction of CQ-induced SMON to Japan. Given a re-emergence of CQ and related analogues as neuroprotectants, it is crucial to understand the underlying mechanism of CQ-induced toxicity to prevent any potential CQ-associated risks to future patients.
View Article and Find Full Text PDFLaser-scribed Graphene Electrodes Functionalized with Nafion/FeO Nanohybrids for the Ultrasensitive Detection of Neurotoxin Drug Clioquinol.
ACS Omega
May 2022
Department of Mechanical Engineering, National Taipei University of Technology, Taipei 106, Taiwan.
The analysis of pharmaceutical active ingredients plays an important role in quality control and clinical trials because they have a significant physiological effect on the human body even at low concentrations. Herein, a flexible three-electrode system using laser-scribed graphene (LSG) technology, which consists of Nafion/FeO nanohybrids immobilized on LSG as the working electrode and LSG counter and reference electrodes on a single polyimide film, is presented. A Nafion/FeO/LSG electrode is constructed by drop coating a solution of Nafion/FeO, which is electrostatically self-assembled between positively charged FeO and negatively charged Nafion on the LSG electrode and is used for the first time to determine a neurotoxicity drug (clioquinol; CQL) in biological samples.
View Article and Find Full Text PDF[Fifity years after the identification of the cause of SMON].
Rinsho Shinkeigaku
February 2021
Department of Neurology, National Hospital Organization Suzuka Hospital.
SMON (subacute myelo-optico-neuropathy) is toxic neurological disease which had a profound impact on the population in Japan in 1960's. The clinical characteristics of SMON includes an ascending sensory disturbance, spasticity, and visual impairment typically following abdominal symptoms. Infection was first suspected as an underlying cause of this epidemic.
View Article and Find Full Text PDFA Novel Targeted and High-Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease.
Adv Sci (Weinh)
October 2020
School of Life Sciences Tianjin University 92 Weijin Road, Nankai District Tianjin 300072 P. R. China.
Alzheimer's disease (AD) remains the most prevalent neurodegenerative disease, and no effective treatment is available yet. Metal-ion-triggered aggregates of amyloid-beta (A) peptide and acetylcholine imbalance are reported to be possible factors in AD pathogenesis. Thus, a combination therapy that can not only inhibit and reduce A aggregation but also simultaneously regulate acetylcholine imbalance that can serve as a potential treatment for AD is needed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!